These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11249131)

  • 1. N-Acyl-1,2,3,4a,5,10b-hexahydro-[1]benzopyrano-[3,4-b][1,4]oxazine-9-carbonitriles as bladder-selective potassium channel openers.
    Chiu I; Lin YC; Cheng CY; Tsai MC; Yu HC
    Bioorg Med Chem; 2001 Feb; 9(2):383-93. PubMed ID: 11249131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of 2,3,4a,11b-tetrahydro-oxazino[2,3-c]benzopyran-9-carbonitriles as ATP-sensitive potassium channel openers.
    Cheng CY; Chiu HI; Chang MJ; Lin YC; Tsai MC; Yu HC
    Bioorg Med Chem Lett; 1998 Mar; 8(5):463-8. PubMed ID: 9871599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the effects of several potassium-channel openers on rat bladder and rat portal vein in vitro.
    Edwards G; Henshaw M; Miller M; Weston AH
    Br J Pharmacol; 1991 Mar; 102(3):679-86. PubMed ID: 1364839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-Arylated pyrrolidin-2-ones and morpholin-3-ones as potassium channel openers.
    Liang PH; Hsin LW; Cheng CY
    Bioorg Med Chem; 2002 Oct; 10(10):3267-76. PubMed ID: 12150872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and pharmacological evaluation of thiopyran analogues of the dopamine D3 receptor-selective agonist (4aR,10bR)-(+)-trans-3,4,4a,10b-tetrahydro-4-n-propyl-2H,5H [1]b enzopyrano[4,3-b]-1,4-oxazin-9-ol (PD 128907).
    van Vliet LA; Rodenhuis N; Dijkstra D; Wikström H; Pugsley TA; Serpa KA; Meltzer LT; Heffner TG; Wise LD; Lajiness ME; Huff RM; Svensson K; Sundell S; Lundmark M
    J Med Chem; 2000 Jul; 43(15):2871-82. PubMed ID: 10956195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. (-)-(9S)-9-(3-Bromo-4-fluorophenyl)-2,3,5,6,7,9-hexahydrothieno[3,2-b]quinolin-8(4H)-one 1,1-dioxide (A-278637): a novel ATP-sensitive potassium channel opener efficacious in suppressing urinary bladder contractions. I. In vitro characterization.
    Gopalakrishnan M; Buckner SA; Whiteaker KL; Shieh CC; Molinari EJ; Milicic I; Daza AV; Davis-Taber R; Scott VE; Sellers D; Chess-Williams R; Chapple CR; Liu Y; Liu D; Brioni JD; Sullivan JP; Williams M; Carroll WA; Coghlan MJ
    J Pharmacol Exp Ther; 2002 Oct; 303(1):379-86. PubMed ID: 12235274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relaxant effects of potassium-channel openers on normal and hyper-reflexic detrusor muscle.
    Martin SW; Radley SC; Chess-Williams R; Korstanje C; Chapple CR
    Br J Urol; 1997 Sep; 80(3):405-13. PubMed ID: 9313658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and SAR of novel potassium channel openers targeted for urge urinary incontinence. 1. N-Cyanoguanidine bioisosteres possessing in vivo bladder selectivity.
    Butera JA; Antane MM; Antane SA; Argentieri TM; Freeden C; Graceffa RF; Hirth BH; Jenkins D; Lennox JR; Matelan E; Norton NW; Quagliato D; Sheldon JH; Spinelli W; Warga D; Wojdan A; Woods M
    J Med Chem; 2000 Mar; 43(6):1187-202. PubMed ID: 10737752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the potassium channel openers, WAY-133537, ZD6169, and celikalim on isolated bladder tissue and In vivo bladder instability in rat.
    Wojdan A; Freeden C; Woods M; Oshiro G; Spinelli W; Colatsky TJ; Sheldon JH; Norton NW; Warga D; Antane MM; Antane SA; Butera JA; Argentieri TM
    J Pharmacol Exp Ther; 1999 Jun; 289(3):1410-8. PubMed ID: 10336534
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo comparison of two K+ channel openers, diazoxide and cromakalim, and their inhibition by glibenclamide.
    Quast U; Cook NS
    J Pharmacol Exp Ther; 1989 Jul; 250(1):261-71. PubMed ID: 2501478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levcromakalim may induce a voltage-independent K-current in rat portal veins by modifying the gating properties of the delayed rectifier.
    Edwards G; Ibbotson T; Weston AH
    Br J Pharmacol; 1993 Nov; 110(3):1037-48. PubMed ID: 8298792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional study on the effects of nifedipine, cromakalim, and the absence of extracellular Ca2+ on alpha 1-adrenoceptor-mediated excitation-contraction coupling in isolated rat portal vein: comparison with depolarization-mediated excitation-contraction coupling.
    Schwietert R; Wilhelm D; Wilffert B; van Zwieten PA
    J Cardiovasc Pharmacol; 1993 May; 21(5):739-48. PubMed ID: 7685443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of BRL55834 in rat portal vein and bovine trachea: evidence for the induction of a glibenclamide-resistant, ATP-sensitive potassium current.
    Edwards G; Schneider J; Niederste-Hollenberg A; Noack T; Weston AH
    Br J Pharmacol; 1995 Jul; 115(6):1027-37. PubMed ID: 7582499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and pharmacological evaluation of R/S-3,4-dihydro-2,2-dimethyl- 6-halo-4-(phenylaminocarbonylamino)-2H-1-benzopyrans: toward tissue-selective pancreatic beta-cell KATP channel openers structurally related to (+/-)-cromakalim.
    Sebille S; Gall D; de Tullio P; Florence X; Lebrun P; Pirotte B
    J Med Chem; 2006 Jul; 49(15):4690-7. PubMed ID: 16854075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The involvement of potassium channels in the action of ciclazindol in rat portal vein.
    Noack T; Edwards G; Deitmer P; Greengrass P; Morita T; Andersson PO; Criddle D; Wyllie MG; Weston AH
    Br J Pharmacol; 1992 May; 106(1):17-24. PubMed ID: 1504725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacologic profiles of YM934, a novel potassium channel opener.
    Uchida W; Masuda N; Taguchi T; Shibasaki K; Shirai Y; Asano M; Matsumoto Y; Tsuzuki R; Fujikura T; Takenaka T
    J Cardiovasc Pharmacol; 1994 Feb; 23(2):180-7. PubMed ID: 7511745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein.
    Pataricza J; Hõhn J; Petri A; Balogh A; Papp JG
    J Pharm Pharmacol; 2000 Feb; 52(2):213-7. PubMed ID: 10714952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of vascular KATP channels in hypothyroidism.
    Jagadish M; Raviprakash V; Telang AG; Mishra SK
    Eur J Pharmacol; 1996 Aug; 309(1):63-9. PubMed ID: 8864695
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and biological activity of spirocyclic benzopyran imidazolone potassium channel openers.
    Gadwood RC; Kamdar BV; Dubray LA; Wolfe ML; Smith MP; Watt W; Mizsak SA; Groppi VE
    J Med Chem; 1993 May; 36(10):1480-7. PubMed ID: 8496916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potassium channel-opening and vasorelaxant profiles of a novel compound YM099 in rat isolated portal vein and rabbit isolated aorta.
    Uchida W; Hirano Y; Shirai Y; Taguchi T; Masuda N; Shibasaki K; Hirano S; Matsumoto Y; Tsuzuki R; Yanagisawa I
    Arch Int Pharmacodyn Ther; 1994; 327(3):330-43. PubMed ID: 7848015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.